Jaume Pons Ph.D.
Net Worth
Last updated:
What is Jaume Pons Ph.D. net worth?
The estimated net worth of Dr. Jaume Pons Ph.D. is at least $18,843,325 as of 14 Aug 2024. He owns shares worth $512,543 as insider, has earned $13,210,782 from insider trading and has received compensation worth at least $5,120,000 in ALX Oncology Holdings Inc..
What is the salary of Jaume Pons Ph.D.?
Dr. Jaume Pons Ph.D. salary is $1,280,000 per year as Pres, Chief Executive Officer & Director in ALX Oncology Holdings Inc..
How old is Jaume Pons Ph.D.?
Dr. Jaume Pons Ph.D. is 59 years old, born in 1966.
What stocks does Jaume Pons Ph.D. currently own?
As insider, Dr. Jaume Pons Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | Pres, Chief Executive Officer & Director | 591,510 | $0.87 | $512,543 |
What does ALX Oncology Holdings Inc. do?
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Jaume Pons Ph.D. insider trading
ALX Oncology Holdings Inc.
Dr. Jaume Pons Ph.D. has made 23 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,937 units of ALXO stock worth $4,997 on 14 Aug 2024.
The largest trade he's ever made was exercising 50,000 units of ALXO stock on 16 Apr 2024. As of 14 Aug 2024 he still owns at least 591,510 units of ALXO stock.
ALX Oncology Holdings key executives
ALX Oncology Holdings Inc. executives and other stock owners filed with the SEC:
- Dr. Corey S. Goodman Ph.D. (74) Independent Executive Chairman
- Dr. Jaume Pons Ph.D. (59) Pres, Chief Executive Officer & Director
- Dr. Sophia Randolph M.D., Ph.D. (57) Chief Medical Officer & Director
- Mr. Peter S. Garcia (63) Chief Financial Officer